Sphere Bio's Cyto-Cellect Assay Kit integrates viability and antibody detection, streamlining workflows and ensuring optimal selection of high-producing clones.

Novo Nordisk presented new data from the retrospective, observational SCORE study that assessed treatment with semaglutide 2.4 mg and the risk of major adverse cardiovascular events (MACE) in adults ...

On top of noninferior efficacy, the trial showed patients had less bleeding with 2.5 mg vs 5.0 mg twice daily over 12 months.

With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...

Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02. A ...

Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio ...

Reports Continued Progress Across Both Obesity and Oncology FranchisesHOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., ...

Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response ...

The new Bathys MG headphones arrive in warm chestnut brown, a color scheme inspired by another of the brand’s iconic models ...

A phase 2 trial will evaluate leronlimab’s safety and efficacy for the treatment of patients with microsatellite stable ...

The IM5 and IM6, which are already on sale in China under the names L6 and LS6, will be the vehicles taking center stage.

Recently presented THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Strategic alternatives process underway to maximize value creation across ...